Functional alteration of tumor-infiltrating myeloid cells in RNA adjuvant therapy

Anticancer Research

Volumn 35, Issue 8, 2015, Pages 4385-4392

  Seya, Tsukasa ^a   Shime, Hiroaki ^a   Matsumoto, Misako ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antitumor immunotherapy; Dendritic cells (DCs); Myeloid derived suppressor cells (MDSC); Poly(I:C); Review; TICAM 1; Toll like receptor 3; Tumor associated macrophages (TAM)

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CASPASE 8; FAS ASSOCIATED DEATH DOMAIN PROTEIN; INTERFERON REGULATORY FACTOR 3; POLYINOSINIC POLYCYTIDYLIC ACID; RNA; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; IMMUNOLOGICAL ADJUVANT; INDUCIBLE NITRIC OXIDE SYNTHASE; TLR3 PROTEIN, MOUSE;

BONE MARROW CELL; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MACROPHAGE; MYELOID PROGENITOR CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR INFILTRATING MYELOID CELL; TUMOR MICROENVIRONMENT; ANIMAL; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MACROPHAGES; MICE; NEOPLASMS; NITRIC OXIDE SYNTHASE TYPE II; POLY I-C; RNA; TOLL-LIKE RECEPTOR 3; TUMOR MICROENVIRONMENT;

EID: 84939795150     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Iwasaki A and Medzhitov R: Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-995, 2004.
2. Lee J, Sayed N, Hunter A, Au KF, Wong WH, Mocarski ES, Pera RR, Yakubov E and Cooke JP: Activation of innate immunity is required for efficient nuclear reprogramming. Cell 151: 547-558, 2012.
3. Yu P, Lubben W, Slomka H, Gebler J, Konert M, Cai C, Neubrandt L, Prazeres da Costa O, Paul S, Dehnert S, Dohne K, Thanisch M, Storsberg S, Wiegand L, Kaufmann A, Nain M, Quintanilla-Martinez L, Bettio S, Schnierle B, Kolesnikova L, Becker S, Schnare M and Bauer S: Nucleic acid-sensing Toll-like receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumors. Immunity 37: 867-879, 2012.
4. Tatematsu M, Seya T and Matsumoto M: Beyond dsRNA: Tolllike receptor 3 signalling in RNA-induced immune responses. Biochem J 458: 195-201, 2014.
5. Matsumoto M, Kikkawa S, Kohase M, Miyake K and Seya T: Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun 293: 1364-1369, 2002.
6. Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto Y, Yamamoto A and Seya T: Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 171: 3154-3162, 2003.
7. Oshiumi H, Matsumoto M, Funami K, Akazawa T and Seya T: TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 4: 161-167, 2003.
8. Honda K and Taniguchi T: Toll-like receptor signaling and IRF transcription factors. IUBMB Life 58: 290-295, 2006.
9. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ and Yuan J: Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 135: 1311-1323, 2008.
10. Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, Takahashi T, Ikawa M, Okabe M, Inoue N, Okamoto-Tanaka M, Ishizaki H, Miyoshi J, Matsumoto M and Seya T: Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci USA 104: 252-257, 2007.
11. Azuma M, Ebihara T, Oshiumi H, Matsumoto M and Seya T: Cross-priming for antitumor CTL induced by soluble Ag+polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells. Oncoimmunology 1: 581-92, 2012.
12. Seya T, Shime H, Takaki H, Oshiumi H and Matsumoto M: TLR3/TICAM-1 signaling in RIP3 tumor necroptosis. Oncoimmunology 1: 917-923, 2012.
13. Sun L, Wang H, Wang Z, He S, Chen S, Liao D, Wang L, Yan J, Liu W, Lei X and Wang X: Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148: 213-227, 2012.
14. Wang Z, Jiang H, Chen S, Du F and Wang X: The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell 148: 228-243, 2012.
15. Akira S: Toll-like receptor signaling. J Biol Chem 278: 38105- 38108, 2003.
16. Yoneyama M, Onomoto K and Fujita T: Cytoplasmic recognition of RNA. Adv Drug Deliv Rev 60: 841-846, 2008.
17. Tatematsu M, Nishikawa F, Seya T and Matsumoto M: Toll-like receptor 3 recognizes incomplete stem structures in singlestranded viral RNA. Nat Commun 4: 1833, 2013.
18. Ebihara T, Shingai M, Matsumoto M, Wakita T and Seya T: Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. Hepatology 48: 48-58, 2008.
19. Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H, Liu J, Pan T, Chen J, Wu M, Zhou X and Yuan Z: Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity. Nat. Immunol 14: 793-805, 2013.
20. Kono H and Rock KL: How dying cells alert the immune system to danger. Nat Rev Immunol 8: 279-289. 2008.
21. McCartney S, Vermi W, Gilfillan S, Cella M, Murphy TL, Schreiber RD, Murphy KM and Colonna M: Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 206: 2967-2976, 2009.
22. Wynn TA, Chawla A and Pollard JW: Macrophage biology in development, homeostasis and disease. Nature 496: 445-455, 2013.
23. Shime H, Matsumoto M and Seya T: The role of innate immune signaling in regulation of tumor-associated myeloid cells. Springer Book 25-47, 2015.
24. Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, Tahara H, Inoue N and Seya T: Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci USA 109: 2066-2071, 2012.
25. Shime H, Kojima A, Maruyama A, Saito Y, Oshiumi H, Matsumoto M and Seya T: Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models. J Innate Immun 6: 293-305, 2014.
26. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L and Kroemer G: Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. OncoImmunol 1: 699-716, 2012.
27. Ichikawa T, Sugiura H, Koarai A, Minakata Y, Kikuchi T, Morishita Y, Oka A, Kanai K, Kawabata H, Hiramatsu M, Akamatsu K, Hirano T, Nakanishi M, Matsunaga K, Yamamoto N and Ichinose M: TLR3 activation augments matrix metalloproteinase production through reactive nitrogen species generation in human lung fibroblasts. J Immunol 192: 4977-4988, 2014.
28. Hsieh MY, Chang MY, Chen YJ, Li YK, Chuang TH, Yu GY, Cheung CH, Chen HC, Maa MC and Leu TH: The inducible nitric-oxide synthase (iNOS)/Src axis mediates Toll-like receptor 3 tyrosine 759 phosphorylation and enhances its signal transduction, leading to interferon-β synthesis in macrophages. J Biol Chem 289: 9208-20, 2014.
29. Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, Haddad EK, Breton G, Trumpfheller C, Pollak S, Shimeliovich I, Duque-Alarcon A, Pan L, Nelkenbaum A, Salazar AM, Schlesinger SJ, Steinman RM and Sekaly RP: Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 208: 2357-2366, 2011.
30. Matsumoto M, Tatematsu M, Nishikawa F, Azuma M, Ishii N, Morii-Sakai A, Shime H and Seya T: Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. Nat Commun 6: 6280, 2015.
31. Takemura R, Takaki H, Okada S, Shime H, Akazawa T, Oshiumi H, Matsumoto M, Teshima T and Seya T: PolyI:C-induced, TLR3/RIP3-dependent necroptosis backs up immune effectormediated tumor elimination in vivo. Cancer Immunol Res Apr 21. pii: canimm. 0219, 2015.
32. Goutagny N, Estornes Y, Hasan U, Lebecque S and Caux C. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 7: 29-54, 2012.
33. Azuma M, Takeda Y, Nakajima H, Sugiyama H, Ebihara T, Oshiumi H, Matsumoto M, Teshima T and Seya T: BATF3 fundamentally supports TLR3-derived IL-12 induction in CD8+ dendritic cells, which promotes antitumor T cell responses by Poly(I:C). Cancer Res. (submitted), 2015.